Main page screenshot of
Reviewed on Oct 30st, 2019

Otsuka America Corporate Site

Product Labeling Update for SPRYCEL® (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase Data added to SPRYCEL® (dasatinib) U.S. labeling are among the longest follow-up data of current CML treatment options ]]> 6/20/2013 12:00:00 AM 1 U.S Food and Drug Administration Approves Updated Label for Otsuka’s BreathTek® UBT for H.

Competing rank

Related searches

Most popular

Latest searches